The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics of mavacamten in adolescent patients with symptomatic obstructive hypertrophic cardiomyopathy (HCM).
Cardiomyopathy, Hypertrophic
The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics of mavacamten in adolescent patients with symptomatic obstructive hypertrophic cardiomyopathy (HCM).
A Study to Evaluate Mavacamten in Adolescents With Symptomatic Obstructive Hypertrophic Cardiomyopathy
-
The University of Alabama at Birmingham, Birmingham, Alabama, United States, 35294-0004
Phoenix Children's Cardiology, Phoenix, Arizona, United States, 85016-7710
Children's Hospital Los Angeles, Los Angeles, California, United States, 90027-6062
University of California Los Angeles (UCLA) - Mattel Children's Hospital, Los Angeles, California, United States, 90095-8344
Local Institution - 0004, Oakland, California, United States, 94609
Lucile Packard Children's Hospital (LPCH), Palo Alto, California, United States, 94304-1601
Local Institution - 0044, San Diego, California, United States, 92123-4223
Children's Hospital Colorado, Aurora, Colorado, United States, 80045-7106
Johns Hopkins All Children's Hospital, Saint Petersburg, Florida, United States, 33701-4634
Children's Healthcare of Atlanta - Arthur M. Blank Hospital, Atlanta, Georgia, United States, 30329-3117
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
For general information about clinical research, read Learn About Studies.
12 Years to 17 Years
ALL
No
Bristol-Myers Squibb,
Bristol-Myers Squibb, STUDY_DIRECTOR, Bristol-Myers Squibb
2031-03-28